Treatment of renal anemia with recombinant human erythropoietin



Publisher: Karger in Basel, New York

Written in English
Cover of: Treatment of renal anemia with recombinant human erythropoietin |
Published: Pages: 211 Downloads: 38
Share This

Subjects:

  • Renal anemia -- Chemotherapy -- Congresses.,
  • Recombinant erythropoietin -- Therapeutic use -- Congresses.,
  • Anemia -- therapy -- congresses.,
  • Erythropoietin -- therapeutic use -- congresses.,
  • Kidney Diseases -- complications -- congresses.

Edition Notes

Statementvolume editors, K.M. Koch ... [et al.].
SeriesContributions to nephrology ;, vol. 66, Contributions to nephrology ;, v. 66.
ContributionsKoch, K. M.
Classifications
LC ClassificationsRC641.7.R44 T74 1988
The Physical Object
Paginationviii, 211 p. :
Number of Pages211
ID Numbers
Open LibraryOL2031229M
ISBN 103805547641
LC Control Number88006808

The purpose of this study was to estimate the costs and benefits of the use of recombinant human erythropoietin (rHuEpo) in the chronic renal failure anaemia. Although experience in the use of rHuEpo is growing, evidence from controlled studies, addressed toward its impact on patient survival and the importance of side effects, is not available.   Schaefer RM, Horl WH, Massry SG: Treatment ofrenal anemia with recombinant human erythropoietin. Am J Ne­phroI, Ad Hoc Committee for the National Kidney Foun­ ERYTHROPOIETIN AND BLEEDING IN UREMIA dation: Statement on the clinical use of recombinant eryth­ropoietin in anemia of end-stage renal disease. Endogenous erythropoietin is a hormone that is secreted by particular cells in the kidneys in response to reduced levels of oxygen reaching the tissues in the kidneys. Recombinant human erythropoietins are given to patients with kidney failure to treat anemia.   Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease. Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production.

Multiple myeloma (MM) is commonly associated with anemia. Several causes have been implicated but inadequate erythropoietin (Epo) production appears to be important. This single-institute open-label, non-comparative clinical trial was undertaken in order to evaluate serum Epo levels in patients with MM and to study the efficacy and toxicity of reco. The members of the ABHH Committee responsible for writing the guidelines on the treatment of anemia of chronic renal failure using recombinant human erythropoietin prepared the main question related to its treatment. The issue was structured using the Patient/Problem, Intervention, Comparison and Outcome (PICO) system. To the Editor: Treatment with recombinant human erythropoietin can reverse the anemia of renal failure.1,2 In sickle cell anemia, the anemia is rarely severe enough to merit transfusion. The need f. The gene for human erythropoietin was cloned in , 3,4 and recombinant human erythropoietin (epoetin) was approved for marketing in France in for the treatment of anemia in patients.

Chronic kidney disease (CKD) causes anemia by renal damage. In CKD, the kidney is submitted to hypoxia, persistent inflammation, leading to fibrosis and permanent loss of renal function. Human recombinant erythropoietin (rEPO) has been widely used to treat CKD-associated anemia and is known to possess organ-protective properties that are independent from its well-established . Anemia of renal disease is a hypoproliferative anemia resulting primarily from deficient erythropoietin (EPO) or a diminished response to it; it tends to be normocytic and normochromic. Treatment includes measures to correct the underlying disorder and supplementation with EPO and sometimes iron. Objective. The efficacy and safety of recombinant human erythropoietin (rHuEPO) treatment in chemotherapy-induced anemia in children were investigated. rHuEPO is used to treat chemotherapy-induced anemia. Several studies recommend to IU/kg rHuEPO for 2 to 8 months. There are only a few controlled trials in children and no precise data about the optimal dose and duration of rHuEPO. Renal anemia is a greater clinical problem in children than it is in adults because it is much more pronounced in this age group due to a more severe bone marrow hypoproliferation [18, 20, 24, 28, 29]. From this point of view there is a special reason to treat renal anemia of children with recombinant human erythropoietin (rhEpo).

Treatment of renal anemia with recombinant human erythropoietin Download PDF EPUB FB2

Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med. Aug; 89 (2)– Fischl M, Galpin JE, Levine JD, Groopman JE, Henry DH, Kennedy P, Miles S, Robbins W, Starrett B, Zalusky R, et al. Recombinant human erythropoietin for patients with AIDS treated with by: 1.

Get this from a library. Treatment of renal anemia with recombinant human erythropoietin. [K M Koch;]. Treatment with exogenous erythropoietin (EPO) can correct anemia in many with CKD.

We produced 5/6-nephrectomized rats that became uremic and anemic at 25 days post surgery. Injection of the anemic 5/6-nephrectomized rats with mg zinc/kg body weight raised their red blood cell (RBC) levels from approximately 85% of the control to 95% in one Cited by: 1.

Sinnassamy P, Andre JL, Treize G, et al. Effect of treatment with human recombinant erythropoietin on the anemia of children with end-stage renal failure Treatment of renal anemia with recombinant human erythropoietin book multicentre study.

Arch Fr Cited by: Erythropoietin. Stage 5 renal failure patients in chronic peritoneal dialysis with anemia (hematocrit erythropoietin ( U three times weekly if hematocrit was anemia after six to 12 weeks of treatment (number needed to treat [NNT] = 2) when compared to a : Aderson da Silva Araújo, Clarisse Lopes de Castro Lobo, Dimas Tadeu Covas, Fernando Ferreira Costa.

J.W. Eschbach, J.C. Egrie, M.R. Downing, J.K. Browne, J.W. AdamsonCorrection of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

Bone marrow changes following treatment of renal anemia with erythropoietin. In 14 severely anemic patients with end-stage renal disease and chronic hemodialysis the effect of recombinant human erythropoietin (EPO) on hemopoiesis was investigated.

Abstract: The use of recombinant human erythropoietin (rHuEpo) has revolutionized anemia management of early and late stages of chronic kidney disease. Darbopoietin is also now available for the treatment of anemia of chronic kidney disease.

In addition, rHuEpo has been used for the treatment of anemia observed in critical illness. Recombinant human erythropoietin (rHuEPO), used clinically for renal anemia, reportedly exhibits pleiotropic properties in various tissues.

To test whether it ameliorates vascular injury, rHuEPO (75U/kg) was administered subcutaneously every 3days for 10days to 5/6 nephrectomized hypertensive rats (5/6Nx) treated with 1% NaCl.

rHuEPO had no effect on increased systolic blood pressure or. Patient with renal diseases or nephrectomy (bilateral) has low EP level.

Decreased EP level is seen in a patient with Malignant polycythemia vera. Erythropoietin role in renal failure: EP as recombinant human erythropoietin is very effective in the treatment of anemia due to chronic renal failure, in patients who are on dialysis.

HUMAN RECOMBINANT ERYTHROPOIETIN IN THE TREATMENT OF ANEMIA OF PATIENTS WITH CHRONIC RENAL FAILURE Isam Hamo Mahmood1, Emadeldin Ibrahim Al-badrani2 & Najlaa Saadi3 ABSTRACT Objective: To compare the effect of small doses of recombinant erythropoietin on anemia of patients with chronic kidney disease who need dialysis and those are not on dialysis.

Exogenous replacement of erythropoietin by recombinant human erythropoietin has been considered a standard of care for the treatment of anemia in patients with chronic kidney disease for more than 20 years.

Genetically-engineered biologic proteins derived. The approval of recombinant human erythropoietin in drastically shifted the treatment of renal anemia. While the initial goal of treating anemia of chronic kidney disease with erythropoietin was to prevent blood transfusions, subsequent studies showed that the benefits might be far : Urology, Urology.

While recombinant human EPO (rhEPO) are employed for treating anemia observed with renal failure (Cody & Hodson, ), the treatment with rhEPO poses a risk of cardiovascular morbidities. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.

N Engl J Med ; Personal communication, Regulatory Affairs Officer, Geigy Canada, 10/25/ A special form of anemia was observed during the treatment with recombinant human erythropoietin having been applied for more than 15 years.

The pure red-cell anemia due to antibodies against erythropoietin was described in chronic renal failure patients. Since oncological patients are also treated.

The effectiveness of recombinant human erythropoietin (r-HEPO) was tested in 15 haemodialysis patients. The dosage was started at 24 IU/kg three times weekly, as an intravenous bolus at the end of the dialysis session, and then doubled every two weeks as. Recombinant human erythropoietin can rapidly correct anemia and symptoms associated with COVID‐19 – Through cytokine modulation, rhEPO exerts its cytoprotective and anti‐apoptotic effects in COVID pneumonia.

– rhEPO takes iron away from intracellular virus into the bone marrow, undermining the viral enzymatic requirements. Recombinant erythropoietin is a man-made version of natural erythropoietin. It is produced by cloning the gene for erythropoietin.

Recombinant erythropoietin drugs are known as erythropoietin-stimulating agents (ESAs). These drugs are given by injection (shot) and work by stimulating the production of more red blood cells. To examine the effects of erythropoietin on the anemia of chronic renal disease and on the rate of renal deterioration, we administered recombinant human erythropoietin to 17 patients with anemia.

Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n,-r ə-,-p ɔɪ ˈ ɛ t ɪ n,-ˈ iː t ɪ n /; EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidney in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone levels of EPO (around 10 mU/mL) are constantly.

Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis. Recombinant Human Erythropoiesis Injection (CHO cell) rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin. Other Name: rHuEPO.

Keywords:Antianemic, Peformance enhancing drug, Recombinant Human Erythropoietin, Erythropoiesis, Growth factors, Androgens. Abstract: The glycoprotein hormone erythropoietin is an essential viability and growth factor for the erythrocytic progenitors in the bone marrow.

Tissue hypoxia is the main stimulus for the synthesis of the hormone in. Explore the latest full-text research PDFs, articles, conference papers, preprints and more on CELLULAR FUNCTION. Find methods information, sources, references or conduct a literature review on.

Therapy with recombinant human erythropoietin (rhEPO) has become most valuable for the treatment of renal anemia in patients with various chronic renal diseases. For the first time this study presents data showing that rhEPO affects the metabolism of folic acid.

There were 13. N2 - Much progress has been made in recent years in the management of anemia associated with chronic renal failure with recombinant human erythropoietin (r-Hu EPO).

However, there remains much debate surrounding the diagnosis and treatment of iron deficiency. Abstract. It has long been the aim of nephrologists to treat the anaemia of patients with chronic renal failure with erythropoietin.

Although aware that many factors contribute to the development of this anaemia they were confident that replacement treatment would be effective (1). Abstract. Several factors have been involved in the pathogenesis of uraemic anaemia: inhibition of erythropoiesis and hyperhaemolysis to uraemic toxins (1); iron deficiency due to blood losses in the extracorporeal circuit (2); severe hyperparathyroidism with osteitis fibrosa (3) ; abnormally high concentrations of aluminium (4).

Treatment with recombinant human erythropoietin in pre-dialysis patients corrects anaemia, avoids the requirement for blood transfusions and also improves quality of life and exercise capacity.

[11, 12] Prevention. Restricting the progression of CKD. Recombinant human erythropoietin (epoetin) is widely used for correction of anaemia in patients with chronic renal disease and its efficacy has been confirmed in numerous studies.

Disturbances in carnitine metabolism may also contribute to the development of renal anaemia. Jaroslaw P. Maciejewski, Swapna Thota, in Hematology (Seventh Edition), Erythropoietin Antibody–Associated PRCA. Recombinant erythropoietin is used in the treatment of anemia of various origins, including anemia of chronic disease, renal disease, and a variety of bone marrow failure syndromes, particularly myelodysplastic syndrome (MDS).

Cases of PRCA have developed as a .The production of erythropoietin (EPO) by the kidneys, a principal hormone for the hematopoietic system, is reduced in patients with chronic kidney disease (CKD), eventually resulting in severe anemia.

Although recombinant human EPO treatment improves anemia in patients with CKD, returning to full r .Anemia is a severe complication in patients with chronic kidney disease (CKD).

Treatment with exogenous erythropoietin (EPO) can correct anemia in many with CKD. We produced 5/6-nephrectomized rats that became uremic and anemic at 25 days post surgery. Injection of the anemic 5/6-nephrectomized rats with mg zinc/kg body weight raised their red blood cell (RBC) levels from .